Use of nafarelin to investigate the pathophysiology of the polycystic ovary syndrome.
Although gonadotropin releasing hormone analog therapy successfully suppresses gonadotropin secretion and excess ovarian androgen production, it does not break the cycle of disordered hormonal patterns that perpetuates the syndrome.
Shaw
R W
RW
Academic Department of Obstetrics and Gynaecology, Royal Free Hospital School of Medicine, London, England.
D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D017274:Nafarelin; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy / Q000503:physiopathology*
D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone